<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762265</url>
  </required_header>
  <id_info>
    <org_study_id>EFC17092</org_study_id>
    <secondary_id>PRN1008-012</secondary_id>
    <nct_id>NCT03762265</nct_id>
  </id_info>
  <brief_title>A Study of PRN1008 in Patients With Pemphigus</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Principia Biopharma, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded&#xD;
      Treatment Period) followed by an Open-Label Extension Period intended to evaluate the&#xD;
      efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the&#xD;
      Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period&#xD;
      of 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 120 male or female patients with newly diagnosed or relapsing moderate to&#xD;
      severe pemphigus (pemphigus vulgaris [PV] or pemphigus foliaceus [PF]) will be enrolled in&#xD;
      the trial worldwide.&#xD;
&#xD;
      The trial will last 68 weeks (approximately 17 months) for each participant. For patients&#xD;
      eligible to enroll in the Long Term Extension, the trial may last up to 116 weeks.&#xD;
&#xD;
      Patients will be randomized at Day 1, using a 1:1 ratio to receive PRN1008 or placebo twice&#xD;
      per day, by relapsing/newly diagnosed disease history (newly diagnosed defined as within 6&#xD;
      months of Screening).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Anticipated">December 8, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who are in Complete Remission (CR) with a corticosteroids (CS) dose of ≤5 mg/day</measure>
    <time_frame>From Week 29 to Week 37</time_frame>
    <description>Complete Remission (CR) defined as the absence of new and established lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Corticosteroids (CS) dose</measure>
    <time_frame>From Baseline to Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of CR with a CS dose ≤10 mg/day</measure>
    <time_frame>From Baseline to Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first CR with a CS dose ≤10 mg/day</measure>
    <time_frame>From Baseline to Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with at least one disease relapse/flare from initial control of disease activity (CDA) to Week 37</measure>
    <time_frame>Up to Week 37</time_frame>
    <description>Control of disease activity (disease control) is defined as the visit at which new lesions cease to form and established lesions begin to heal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of CR with a CS dose ≤10 mg/day</measure>
    <time_frame>From Week 37 to Week 61</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of CR with a CS dose = 0 mg/day</measure>
    <time_frame>From Week 37 to Week 61</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who are in CR from Week 29 to Week 37 with a CS dose of ≤10 mg/day</measure>
    <time_frame>From Week 29 to Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who have a PDAI score &lt;3 from Week 29 to Week 37 with a CS dose ≤10 mg/day</measure>
    <time_frame>From week 29 to week 37</time_frame>
    <description>The Pemphigus disease area index (PDAI) total activity score is a clinical assessment with a possible rater score ranging from 0 to 250, consisting of ≤120 points for skin activity, ≤10 points for scalp activity, and ≤120 points for mucosal activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of CR with a CS dose ≤10 mg/day</measure>
    <time_frame>Until Week 109</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of CR with a CS dose = 0 mg/day</measure>
    <time_frame>Until Week 109</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GTI score at Week 37</measure>
    <time_frame>At Week 37</time_frame>
    <description>Glucocorticoid toxicity index (GTI) is a copyrighted instrument for measurement of CS toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PDAI score</measure>
    <time_frame>Until Week 109</time_frame>
    <description>The Pemphigus disease area index (PDAI) total activity score is a clinical assessment with a possible rater score ranging from 0 to 250, consisting of ≤120 points for skin activity, ≤10 points for scalp activity, and ≤120 points for mucosal activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Autoimmune Bullous Disease Quality of Life (ABQOL) score</measure>
    <time_frame>Until Week 109</time_frame>
    <description>The ABQOL questionnaire is a 17-item questionnaire assessing quality of life in participants with autoimmune blistering diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ABQOL Score of zero</measure>
    <time_frame>Until Week 109</time_frame>
    <description>The ABQOL questionnaire is a 17-item questionnaire assessing quality of life in participants with autoimmune blistering diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQOL-5 Dimension 5 Level (EQ-5D-5L) results (visual analog scale [VAS] results and individual dimension) scores</measure>
    <time_frame>Until Week 109</time_frame>
    <description>EQ-5D-5L questionnaire has 5 dimensions: &quot;Mobility&quot;, &quot;Self-Care,&quot; &quot;Usual Activities&quot;, &quot;Pain/Discomfort&quot;, &quot;Anxiety/Depression&quot;, and all dimensions are described by 5 problem levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first CR with a CS dose ≤10 mg/day</measure>
    <time_frame>Until Week 109</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of disease relapses/flares from initial CDA to Week 37</measure>
    <time_frame>At Week 37</time_frame>
    <description>Control of disease activity (disease control) is defined as the visit at which new lesions cease to form and established lesions begin to heal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initial relapse/flare from initial CDA to Week 37</measure>
    <time_frame>At Week 37</time_frame>
    <description>Control of disease activity (disease control) is defined as the visit at which new lesions cease to form and established lesions begin to heal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with 3 or more new lesions within 1 month that do not heal spontaneously within 1 week, or with extension of established lesions</measure>
    <time_frame>From Baseline to Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events</measure>
    <time_frame>Until Week 109</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Pemphigus</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilzabrutinib Oral Tablet</intervention_name>
    <description>Bruton's tyrosine kinase (BTK) inhibitor</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants, aged 18 to 80 years old with moderate to severe, newly&#xD;
             diagnosed or relapsing PV (pemphigus vulgaris) or PF (pemphigus foliaceus), with a&#xD;
             clinical presentation and histopathology consistent with PV or PF.&#xD;
&#xD;
          -  Positive circulating anti-dsg1 or 3 autoantibody titer.&#xD;
&#xD;
          -  At Screening, Pemphigus disease area index (PDAI) score of at least 9 points for&#xD;
             relapsing participants or at least 15 points for newly diagnosed participants.&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal function.&#xD;
&#xD;
          -  Effective means of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected paraneoplastic pemphigus and other forms of pemphigus that are not pemphigus&#xD;
             vulgaris or pemphigus foliaceus.&#xD;
&#xD;
          -  Previous use of a Bruton tyrosine kinase (BTK) inhibitor.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Electrocardiogram (ECG) clinically significant abnormalities.&#xD;
&#xD;
          -  A history of malignancy of any type within 5 years before Day 1, other than surgically&#xD;
             excised non-melanoma skin cancers or in situ cervical cancer.&#xD;
&#xD;
          -  Use of immunologic response modifiers as concomitant medication and with the washout&#xD;
             period.&#xD;
&#xD;
          -  Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days&#xD;
             of Day 1.&#xD;
&#xD;
          -  Concomitant use of known strong-to-moderate inducers or inhibitors of CYP3A within 3&#xD;
             days or 5 half-lives (whichever is longer) of Day 1&#xD;
&#xD;
          -  Use of CYP3A-sensitive substrate drugs.&#xD;
&#xD;
          -  Has received any investigational drug within the 30 days before Day 1.&#xD;
&#xD;
          -  History of drug abuse within the previous 12 months.&#xD;
&#xD;
          -  Alcoholism or excessive alcohol use.&#xD;
&#xD;
          -  Any other clinically significant disease, condition or medical history that, in the&#xD;
             opinion of the Investigator, would interfere with participant safety, trial&#xD;
             evaluations, and/or trial procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1663GJR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1199ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>San Nicolás</city>
        <zip>B2900DPA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Melbourne</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Sydney</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Campinas</city>
        <zip>87131-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Campo Grande</city>
        <zip>79080-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14051-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Sofia</city>
        <zip>01431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Münster</city>
        <zip>48151</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Ioánnina</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Larisa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Florence</city>
        <zip>50121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Rome</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Torino</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Kraków</city>
        <zip>31-066</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Warsaw</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Wrocław</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Dalin</city>
        <zip>62247</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Fatih</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Konyaaltı</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Merkez</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Dnipro</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Dnipro</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Kyiv</city>
        <zip>04209</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Recruiting (Principia Biopharma)</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pemphigus Vulgaris (PV)</keyword>
  <keyword>Pemphigus Foliaceus (PF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

